Effect of CYP3A5 genotype on the extent of CYP3A inhibition by verapamil.

被引：3
|
作者：
Wang, Y [1 ]
Jin, Y [1 ]
Hilligoss, JK [1 ]
Ho, H [1 ]
Hamman, MA [1 ]
Hu, Z [1 ]
Gorski, JC [1 ]
Hall, SD [1 ]
机构：
[1] Indiana Univ, Sch Med, Indianapolis, IN USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2005年 / 77卷 / 02期
关键词：
D O I：
10.1016/j.clpt.2004.11.014
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P3 / P3
页数：1
相关论文
共 50 条
  • [31] Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects
    Kyoung-Ah Kim
    Pil-Whan Park
    Ji-Young Park
    European Journal of Clinical Pharmacology, 2008, 64 : 589 - 597
  • [32] Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients
    Willrich, Maria Alice V.
    Rodrigues, Alice C.
    Cerda, Alvaro
    Genvigir, Fabiana D. V.
    Arazi, Simone S.
    Dorea, Egidio L.
    Bernik, Marcia M. S.
    Bertolami, Marcelo C.
    Faludi, Andre
    Largura, Alvaro
    Baudhuin, Linnea M.
    Bryant, Sandra C.
    Hirata, Mario Hiroyuki
    Crespo Hirata, Rosario Dominguez
    CLINICA CHIMICA ACTA, 2013, 421 : 157 - 163
  • [33] 4β-Hydroxycholesterol is a new endogenous CYP3A marker:: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians
    Diczfalusy, Ulf
    Miura, Jun
    Roh, Hyung-Keun
    Mirghani, Rajaa A.
    Sayi, Jane
    Larsson, Hanna
    Bodin, Karl G.
    Allqvist, Annika
    Jande, Mary
    Kim, Jong-Wook
    Aklillu, Eleni
    Gustafsson, Lars L.
    Bertilsson, Leif
    PHARMACOGENETICS AND GENOMICS, 2008, 18 (03): : 201 - 208
  • [34] Effect of CYP3A5 genotype on ketoconazole induced QT prolongation.
    Vuppalanchi, R
    Lucksiri, A
    Lang, L
    Hilligoss, J
    Flockhart, D
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P5 - P5
  • [35] Effect of CYP3A5 genotype on cyclosporine disposition: A pilot study.
    Yates, CR
    Zhang, W
    Song, P
    Gaber, AO
    Honaker, MR
    Kotb, M
    Alloway, RR
    Meibohm, B
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P2 - P2
  • [36] Effect of CYP3A5 Genotype on Renal Allograft Recipients Treated With Tacrolimus
    Chen, J. S.
    Li, L. S.
    Cheng, D. R.
    Ji, S. M.
    Sun, Q. Q.
    Cheng, Z.
    Wen, J. Q.
    Sha, G. Z.
    Liu, Z. H.
    TRANSPLANTATION PROCEEDINGS, 2009, 41 (05) : 1557 - 1561
  • [37] Association between the CYP3A5 genotype and blood pressure
    Ho, H
    Pinto, A
    Hall, SD
    Flockhart, DA
    Li, L
    Skaar, TC
    Cadman, P
    O'Connor, DT
    Wagner, U
    Fineberg, NS
    Weinberger, MH
    HYPERTENSION, 2005, 45 (02) : 294 - 298
  • [38] A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype
    MacPhee, Iain A. M.
    Holt, David W.
    TRANSPLANTATION, 2008, 85 (02) : 163 - 165
  • [39] CYP3A5 genotype is associated with elevated blood pressure
    Fromm, MF
    Schmidt, BMW
    Pahl, A
    Jacobi, J
    Schmieder, RE
    PHARMACOGENETICS AND GENOMICS, 2005, 15 (10): : 737 - 741
  • [40] Clinical Relevance of CYP3A5 Genotype on Maraviroc Exposures
    Vourvahis, Manoli
    Mcfadyen, Lynn
    Heera, Jayvant
    Clark, Andrew
    DRUG METABOLISM AND DISPOSITION, 2015, 43 (05) : 771 - 772
12345